Dr. Mira Pochron is a dynamic leader in translational biology, with a proven track record of driving biomarker strategy, pharmacodynamic research, and rare disease drug development. As Director of Translational Medicine, she has led multidisciplinary teams in both preclinical and clinical research, overseeing biomarker evaluation, clinical study operations, and regulatory submissions. Her leadership was instrumental in the development of Oxbryta®, the 2021 Prix Galien award-winning biotechnology product. At Pfizer (formerly Global Blood Therapeutics), Dr. Pochron managed cross-functional research teams, guiding innovative biomarker implementation in sickle cell disease therapeutics. Through her consulting practice, Pochron Solutions, LLC, she continues to influence the field, offering strategic direction for biomarker analysis and drug development programs. Dr. Pochron holds a Ph.D. in Chemistry and Biochemistry from the University of California, Santa Cruz, and is widely recognized for her biomarker work in sickle cell disease.